Plus   Neg

Regeneron Announces Pricing Of Secondary Offering Of Its Stock Held By Sanofi At $515.00/shr

Regeneron Pharmaceuticals Inc. (REGN) announced the pricing of the underwritten public secondary offering of about 11.83 million shares of its common stock held by Sanofi at a price of $515.00 per share.

Regeneron also agreed to purchase 9.81 million shares directly from Sanofi, at a price of $509.85 per share, which represents he price paid by the underwriters in the offering, for an aggregate purchase amount of $5 billion.

The underwriters have a 30-day option to purchase up to an additional 1.18 million Regeneron shares from Sanofi. Sanofi will have disposed of all of its shares, other than 400,000 shares it intends to retain.

Regeneron said it will not receive any of the proceeds from the sale of shares in the offering.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT